3rd Austrian Biomarker Symposium 2016 Early Diagnostics

The AIT Austrian Institute of Technology with more
than 1260 employees is Austria’s largest, governmental owned Research & Technology Organization which focuses on the key infrastructure technologies in the fields of Energy, Mobility, Digital
Safety & Security, Health & Environment and Innovation Systems.
The AIT Molecular Diagnostics team develops
tailored biomarkers, biosensors and rapid point of
care test applications for life threatening diseases.
Collaborative R&D projects have been successfully
performed with leading industry and academic
organizations. Our long-term vision is to become a
key-player for saliva based diagnostics and generate minimal invasive IVD assays for early disease
detection and therapy monitoring in clinical drug
development programs.
Registration Fees
Early Registration € 200,Regular Registration € 250,-
3rd Austrian Biomarker
Symposium 2016
Students:
Early Registration € 150,Regular Registration € 200,Registration
www.biomarker-development.com
Important Deadlines
Abstract Submission: December 4, 2015
Early Bird Registration: January 10, 2016
Early Diagnostics
March 10 – 11, 2016
Tech Gate Vienna, Austria
Venue
Tech Gate Vienna
Donau City Strasse 1
1220 Vienna
Austria
Contact
[email protected]
www.biomarker-development.com
Confirmed Speakers
About the 3rd Austrian Biomarker
Symposium 2016
Conference Program
Wendy Alderton Abcodia, UK
DAY 1, March 10, 2016
08:45 a.m. – 6 p.m.
Johannes Grillari EverCyte, AT
The Austrian Biomarker Symposium on Early Diagnostics
provides insight knowledge and best practices for biomarkers and technologies in a variety of diseases and diagnostic applications. Speakers from academic and clinical
institutions and industry will cover key topics in personalized medicine. The past Austrian Biomarker Symposium
attracted diverse experts from biotech, public institutions
and pharma.
Sam Hanash McCombs Institute for the Early Detection and
Treatment of Cancer, USA
KEYNOTE Speakers
Christoph Bock Center of Molecular Medicine (CEMM), AT
Anna Dixon Atlas Diagnostics, UK
David Dolinger FIND, CH
Elvira Fortunato Universidade Nova de Lisboa, P
Jörg Hoheisl DKFZ Heidelberg, DE
Alexandra Kautzky-Willer Medical University Vienna, AT
Mikael Kubista TATAA, SE
Parag Mallick Canary Center at Stanford University, USA
Ulf Landegren Uppsala University, SE
Eckart Meese University of Saarland, DE
Key topics
Willem Ouwehand University of Cambridge, UK
• Personalized Medicine & Early Diagnosis
Philipp Schatz metanomicshealth, DE
• Big Data & Systems Biology
Reinhard Schneider University of Luxembourg, L
Max Sonnleitner Greiner BioOne, AT
Uwe Staub Epigenomics, DE
Klemens Vierlinger AIT Austrian Institute of Technology, AT
Rolf Ziesche Medical University of Vienna, AT
• Novel Sensor Technologies & Point of Care Diagnostics
• Circulating Biomarkers
• Cutting Edge Biomarker Technologies
www.biomarker-development.com
Session 1
Personalized Medicine and Early Diagnosis
Chair: Wendy Alderton
Session 2
Big Data & Systems Biology
Chair: Reinhard Schneider
DAY 2, March 11, 2016
09 a.m. – 5 p.m.
Session 3
Novel Sensor Technologies & POC
Chair: Max Sonnleitner
Session 4
Circulating Biomarkers
Chair: Eckart Meese
Session 5
Cutting Edge Biomarker Technologies
Chair: Jörg Hoheisl

Download Report